India pharma companies develop versions of Wegovy to get in on weight-loss windfall

Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy's, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pElmxC4
via IFTTT